Olmesartan

Generic Name: Olmesartan

Brand Names: Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₆O_₃

CAS Number: 144689-24-7

Unique Ingredient Identifier: 8W1IQP3U10

Background: Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...

Indication: Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...

Associated Conditions: Diabetic Nephropathy, Hypertension

Associated Therapies: -

Clinical Trials

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: LCZ696
Drug: Olmesartan
Drug: Placebo of LCZ696
Drug: Placebo of Olmesartan

First Posted Date: 2013-02-07

Last Posted Date: 2016-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1438

Registration Number: NCT01785472

Locations: 🇹🇭
Novartis Investigative Site, Rajathevee, Thailand

Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Phase 3

Completed

Conditions: Hypertension
Dyslipidemia

Interventions: Drug: DWJ1276
Drug: Olmesartan
Drug: Rosuvastatin
Drug: Placebo

First Posted Date: 2013-01-09

Last Posted Date: 2013-08-23

Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Target Recruit Count: 150

Registration Number: NCT01764295

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: LCZ696
Drug: Olmesartan
Drug: LCZ696 matching placebo
Drug: Olmesartan matching placebo
Drug: amlodipine
Drug: hydrochlorothiazide

First Posted Date: 2012-09-25

Last Posted Date: 2016-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 454

Registration Number: NCT01692301

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Angiotensin II Blockade and Inflammation in Obesity

Phase 4

Completed

Conditions: Overweight
Obese
Prehypertension
Hypertension

Interventions: Drug: Olmesartan medoxomil

First Posted Date: 2012-09-13

Last Posted Date: 2018-01-03

Lead Sponsor: Virginia Polytechnic Institute and State University

Target Recruit Count: 20

Registration Number: NCT01684748

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Placebo
Drug: Olmesartan
Drug: LCZ696

First Posted Date: 2012-06-08

Last Posted Date: 2015-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 588

Registration Number: NCT01615198

Locations: 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil
Drug: Olmesartan medoxomil
Drug: Olmesartan/amlodipine

First Posted Date: 2012-06-04

Last Posted Date: 2017-02-23

Lead Sponsor: Institut für Pharmakologie und Präventive Medizin

Target Recruit Count: 88

Registration Number: NCT01611077

Locations: 🇩🇪
Praxis Dr. Reimer, Anderbeck, Germany
🇩🇪
Praxis Dr. Zemmrich, Berlin, Germany
🇩🇪
St.-Josefs-Hospital, Cloppenburg, Germany

and more 8 locations

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: LCZ696
Drug: Olmesartan
Drug: Placebo

First Posted Date: 2012-05-15

Last Posted Date: 2015-10-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1161

Registration Number: NCT01599104

Locations: 🇯🇵
Novartis Investigative Site, Saitama, Japan

A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Cresto
Drug: DWJ1276
Drug: Olmetec

First Posted Date: 2011-12-16

Last Posted Date: 2012-04-04

Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Target Recruit Count: 58

Registration Number: NCT01493856

Locations: 🇰🇷
Yonsei University Health System (Yuhs), Seoul, Korea, Republic of

Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cresto
Drug: Olmetec
Drug: Cresto, Olmetec

First Posted Date: 2011-08-12

Last Posted Date: 2012-04-04

Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Target Recruit Count: 36

Registration Number: NCT01415466

Locations: 🇰🇷
Yonsei University Health System (Yuhs), Seoul, Korea, Republic of

Telmisartan, Amlodipine and Flow Mediated Dilation

Phase 4

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Olmesartan medoxomil
Drug: Amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2010-08-12

Last Posted Date: 2011-07-12

Lead Sponsor: Johannes Gutenberg University Mainz

Target Recruit Count: 576

Registration Number: NCT01180205

Locations: 🇩🇪
Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy